Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2002 2
2003 1
2004 4
2006 6
2007 3
2008 3
2009 4
2010 7
2011 7
2012 6
2013 6
2014 10
2015 8
2016 15
2017 10
2018 11
2019 15
2020 8
2021 7
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27173161

126 results

Results by year

Filters applied: . Clear all
Page 1
89Zr-bevacizumab PET imaging in primary breast cancer.
Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schröder CP. Gaykema SB, et al. J Nucl Med. 2013 Jul;54(7):1014-8. doi: 10.2967/jnumed.112.117218. Epub 2013 May 7. J Nucl Med. 2013. PMID: 23651946 Free article. Clinical Trial.
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG. Oosting SF, et al. J Nucl Med. 2015 Jan;56(1):63-9. doi: 10.2967/jnumed.114.144840. Epub 2014 Dec 4. J Nucl Med. 2015. PMID: 25476536 Free article.
Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK. van der Bilt AR, et al. Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26. Clin Cancer Res. 2012. PMID: 23014526
126 results